198 related articles for article (PubMed ID: 36847405)
1. Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-derived Xenograft Mouse Model.
Manriquez Roman C; Sakemura RL; Kimball BL; Jin F; Khadka RH; Adada MM; Siegler EL; Johnson AJ; Kenderian SS
J Vis Exp; 2023 Feb; (192):. PubMed ID: 36847405
[TBL] [Abstract][Full Text] [Related]
2. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Sterner RM; Sakemura R; Cox MJ; Yang N; Khadka RH; Forsman CL; Hansen MJ; Jin F; Ayasoufi K; Hefazi M; Schick KJ; Walters DK; Ahmed O; Chappell D; Sahmoud T; Durrant C; Nevala WK; Patnaik MM; Pease LR; Hedin KE; Kay NE; Johnson AJ; Kenderian SS
Blood; 2019 Feb; 133(7):697-709. PubMed ID: 30463995
[TBL] [Abstract][Full Text] [Related]
3. Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.
Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA
Exp Hematol; 2015 Dec; 43(12):1001-1014.e5. PubMed ID: 26384559
[TBL] [Abstract][Full Text] [Related]
4. What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy?
Taraseviciute A; Broglie L; Phelan R; Bhatt NS; Becktell K; Burke MJ
J Pediatr Hematol Oncol; 2019 Jul; 41(5):337-344. PubMed ID: 30973486
[TBL] [Abstract][Full Text] [Related]
5. Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor.
Zhang R; Deng Q; Jiang YY; Zhu HB; Wang J; Zhao MF
Oncol Rep; 2019 Jun; 41(6):3455-3463. PubMed ID: 30942469
[TBL] [Abstract][Full Text] [Related]
6. Genetic Mechanism of Leukemia Relapse Following CD19 Chimeric Antigen Receptor T Cell Therapy.
Qiu S; Pan Y; Shi S; Omotoyosi FF; Chen K; Guo Z; Lü P
Cancer Biother Radiopharm; 2022 Jun; 37(5):335-341. PubMed ID: 33739864
[TBL] [Abstract][Full Text] [Related]
7. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
Braendstrup P; Levine BL; Ruella M
Cytotherapy; 2020 Feb; 22(2):57-69. PubMed ID: 32014447
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.
Myers RM; Dolan J; Teachey DT
Expert Rev Clin Immunol; 2020 Oct; 16(10):1029-1042. PubMed ID: 32975147
[TBL] [Abstract][Full Text] [Related]
9. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
Lee YG; Guruprasad P; Ghilardi G; Pajarillo R; Sauter CT; Patel R; Ballard HJ; Hong SJ; Chun I; Yang N; Amelsberg KV; Cummins KD; Svoboda J; Gill S; Chong EA; North K; Church SE; Fraietta JA; Chang WJ; Lacey SF; Lu XM; Zhang Y; Whig K; Schultz DC; Cherry S; Gerson J; Schuster SJ; Porazzi P; Ruella M
Cancer Discov; 2022 Oct; 12(10):2372-2391. PubMed ID: 35904479
[TBL] [Abstract][Full Text] [Related]
10. A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells.
Ruella M; Barrett DM; Shestova O; Perazzelli J; Posey AD; Hong SJ; Kozlowski M; Lacey SF; Melenhorst JJ; June CH; Gill SI
Blood; 2020 Feb; 135(7):505-509. PubMed ID: 31703119
[TBL] [Abstract][Full Text] [Related]
11. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
13. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021.
Gauthier J; Turtle CJ
Cancer J; 2021 Mar-Apr 01; 27(2):98-106. PubMed ID: 33750068
[TBL] [Abstract][Full Text] [Related]
14. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.
Hu Y; Sun J; Wu Z; Yu J; Cui Q; Pu C; Liang B; Luo Y; Shi J; Jin A; Xiao L; Huang H
J Hematol Oncol; 2016 Aug; 9(1):70. PubMed ID: 27526682
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies.
Garcia-Prieto CA; Villanueva L; Bueno-Costa A; Davalos V; González-Navarro EA; Juan M; Urbano-Ispizua Á; Delgado J; Ortiz-Maldonado V; Del Bufalo F; Locatelli F; Quintarelli C; Sinibaldi M; Soler M; Castro de Moura M; Ferrer G; Urdinguio RG; Fernandez AF; Fraga MF; Bar D; Meir A; Itzhaki O; Besser MJ; Avigdor A; Jacoby E; Esteller M
J Natl Cancer Inst; 2022 Mar; 114(3):436-445. PubMed ID: 34581788
[TBL] [Abstract][Full Text] [Related]
16. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
[TBL] [Abstract][Full Text] [Related]
17. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
[TBL] [Abstract][Full Text] [Related]
18. Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia.
Heng G; Jia J; Li S; Fu G; Wang M; Qin D; Li Y; Pei L; Tian X; Zhang J; Wu Y; Xiang S; Wan J; Zhu W; Zhang P; Zhang Q; Peng X; Wang L; Wang P; Wei Z; Zhang Y; Wang G; Chen X; Zhang C; Sun Y; Zhao W; Fan Y; Yang Z; Chen J; Qian C
Clin Cancer Res; 2020 Apr; 26(7):1606-1615. PubMed ID: 31732519
[TBL] [Abstract][Full Text] [Related]
19. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
20. CD19 chimeric antigen receptor T cell therapy in leukemia xenograft mouse: Anti-leukemic efficacy, kinetics, and 4-week single-dose toxicity.
Kim JI; Park MY; Kwon E; Kang HJ; Kang BC
Toxicol Appl Pharmacol; 2023 Sep; 475():116628. PubMed ID: 37506978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
